SMILES: C1COCCN1NC2=C(C=C(C=C2)C(F)(F)F)[N+](=O)[O-]
Response: Based on computational predictions from the provided SMILES string (C1COCCN1NC2=C(C=C(C=C2)C(F)(F)F)[N+](=O)[O-]), here are the predicted pharmacokinetic (PK) properties of this drug:

1.  **Oral Bioavailability:** The drug is predicted to have oral bioavailability of less than 20%. This suggests that if administered orally, only a small fraction of the drug would reach systemic circulation, potentially due to poor absorption from the gastrointestinal tract or significant first-pass metabolism in the liver. This low bioavailability indicates that oral administration might be challenging or require high doses.

2.  **Half-Life:** The predicted half-life (Obach model) is 66.00 hours. This is a very long half-life, indicating that the drug would remain in the body for an extended period. A long half-life could allow for less frequent dosing intervals, but it also means a longer time to reach steady-state concentrations and a longer washout period if treatment needs to be discontinued.

3.  **Steady-State Volume of Distribution (VDss):** The predicted steady-state volume of distribution (Lombardo method) is 33.00 L/kg. This is an exceptionally high volume of distribution. A high VDss suggests that the drug extensively distributes into and accumulates within tissues outside of the plasma compartment, rather than remaining primarily in the bloodstream. This extensive tissue binding and sequestration could lead to lower plasma concentrations and potentially prolonged effects or accumulation in specific organs.

In summary, this drug is predicted to exhibit poor oral bioavailability, a very long elimination half-life, and extensive distribution into tissues. These properties collectively suggest that the drug might be difficult to administer orally and, if absorbed, could lead to prolonged systemic and tissue exposure, potentially necessitating careful dosing strategies and monitoring for accumulation. It's crucial to remember that these are computational predictions and would need experimental validation.
============================================================
SMILES: O=[N+]([O-])c1c(NCc2ccccc2)ccc2nonc12
Response: The drug with the SMILES O=[N+]([O-])c1c(NCc2ccccc2)ccc2nonc12 is predicted to have the following pharmacokinetic (PK) properties:

*   **Oral Bioavailability:** Very low, predicted to be less than 20%. This suggests that if administered orally, a significant portion of the drug would not be absorbed into systemic circulation.
*   **Half-Life:** Approximately 99.00 hours. This indicates a very long elimination half-life, meaning the drug would persist in the body for an extended period, suggesting a slow rate of elimination.
*   **Volume of Distribution at Steady State (VDss):** 1.00 L/kg. This value indicates moderate tissue distribution, suggesting that the drug distributes beyond the bloodstream into tissues to some extent, but is not excessively sequestered in tissues.
============================================================
SMILES: Cc1ccc(CNc2ccc3nonc3c2[N+](=O)[O-])cc1
Error: 429 You exceeded your current quota, please check your plan and billing details. For more information on this error, head to: https://ai.google.dev/gemini-api/docs/rate-limits. [violations {
  quota_metric: "generativelanguage.googleapis.com/generate_content_free_tier_requests"
  quota_id: "GenerateRequestsPerMinutePerProjectPerModel-FreeTier"
  quota_dimensions {
    key: "model"
    value: "gemini-2.5-flash"
  }
  quota_dimensions {
    key: "location"
    value: "global"
  }
  quota_value: 10
}
, links {
  description: "Learn more about Gemini API quotas"
  url: "https://ai.google.dev/gemini-api/docs/rate-limits"
}
, retry_delay {
}
]
============================================================
SMILES: [3H]c1ccc2nonc2c1[N+](=O)[O-]
Response: The pharmacokinetic (PK) properties of the drug with the SMILES `c1ccc2nonc2c1[N+](=O)[O-]` (a nitrobenzofurazan derivative, with `[3H]` indicating a tritiated tracer) have been predicted as follows:

*   **Oral Bioavailability:** Predicted to be **low (< 20%)**. This suggests that if administered orally, a significant portion of the drug may not be absorbed into the systemic circulation, potentially leading to variable and low systemic exposure.
*   **Half-life (tÂ½):** Predicted to be **short (1.00 hour)**. A short half-life indicates that the drug is eliminated from the body relatively quickly, meaning frequent dosing might be required to maintain therapeutic concentrations, or a continuous infusion strategy might be considered.
*   **Steady-state Volume of Distribution (VDss):** Predicted to be **1.00 L/kg**. This value suggests that the drug is distributed relatively evenly between plasma and tissues, or slightly more into the tissues than plasma, but not extensively sequestered in peripheral tissues.

**Pharmacokinetic Implications:**

Given these predicted properties:
*   **Low oral bioavailability** could be due to factors like poor permeability, high first-pass metabolism, or efflux transporter activity. This often points towards the need for alternative routes of administration (e.g., intravenous) to achieve adequate systemic exposure.
*   **A short half-life** suggests rapid clearance (metabolism and/or excretion). From a therapeutic perspective, this can necessitate frequent dosing to maintain efficacious concentrations, potentially leading to patient compliance issues or requiring extended-release formulations.
*   **A VDss of 1.00 L/kg** is a moderate volume of distribution. It indicates that the drug does distribute into the body's tissues but is not highly sequestered, which can be influenced by factors like lipophilicity and binding to plasma or tissue proteins.

Overall, these predictions suggest a compound that might face challenges in oral drug development due to limited systemic exposure and require careful dosing regimen design due to its rapid elimination.
============================================================
SMILES: O=[N+]([O-])c1c(NCc2cc(F)cc(Cl)c2)ccc2nonc12
Response: Based on the predictions, the PK properties of the drug with the SMILES string O=[N+]([O-])c1c(NCc2cc(F)cc(Cl)c2)ccc2nonc12 are:

*   **Oral Bioavailability:** Predicted to be low, less than 20%. This suggests that only a small fraction of the drug would be absorbed into the systemic circulation if administered orally.
*   **Half-life:** Predicted to be 303 hours. This indicates a very long elimination half-life, meaning the drug will persist in the body for an extended period.
*   **Volume of Distribution at Steady State (VDss):** Predicted to be 3.00 L/kg. This value suggests that the drug distributes moderately to extensively into body tissues outside the bloodstream.
============================================================
